Introduction
============

Diabetic retinopathy (DR) results in progressive visual deterioration, ranging from mild, moderate, severe to very severe non-proliferative DR (NPDR), with a risk of developing proliferative DR (PDR).[@b1],[@b2] The hyperglycemia in diabetes mellitus (DM) is implicated in the apoptosis of vascular and neuronal cells of the retina, because the rate of DR is high among individual with long-term type 2 DM (T2DM).[@b3] Increases in HbA1c levels are associated with risk of DR, with decreases in HbA1c (achieved through a combination of effective clinical management and a healthy lifestyle), demonstrated to reduce the risk of microvascular complications of the retina.[@b4] Reactive oxygen species (ROS) are contributors to oxidative stress and include superoxide anion (O~2~^--^) and hydroxyl radical (OH·).[@b5] The O~2~^--^ is converted to hydrogen peroxide by superoxide dismutase (SOD), and can be converted to singlet oxygen with the capacity to react with polyunsaturated fatty acids of the lipid layer in the cellular membrane, resulting in lipid peroxidation (LPO).[@b6] At physiological concentrations, nitric oxide (NO) moderates cellular respiration.[@b7] However, at increased concentrations, NO produces nitrosative stress by oxidation of adducts of nitric oxide synthase (NOS) where peroxynitrite (OONO^--^) favors the appearance of reactive nitrogen species (RNS). Overproduction of ROS and RNS impedes the correct cellular homeostasis that is associated with DM.[@b8] Increases in NO levels in T2DM are associated with the pathogenesis of DR.[@b9] Mitochondrial dysfunction in DR and the disruption of cellular homeostasis in DM play critical roles in retinal cell death due to changes in mitochondrial morphology, potential heterogeneity of mitochondrial membranes, the rate of oxygen consumption, and poor protein folding promote or favor the disappearance of vascular cells in the retina.[@b10] The aim of the present study was to investigate levels of oxidative stress markers and mitochondrial function in NPDR.

Methods
=======

The present study was a transverse analytical study on 270 T2DM patients (aged between 30 and 75 years) who were unaware of their DR status, with HbA1c ≤12%. Of these patients, 12, 18, and 21 were found to have mild, moderate, and severe NPDR, respectively. Healthy age- and sex-matched volunteers without DM were included as a control group.

Laboratory tests were performed to determine levels of LPO and NO as oxidative stress markers, as well as the total antioxidant capacity (TAC) and catalase and glutathione peroxidase (GPx) activity of erythrocytes. Mitochondrial function was evaluated as the fluidity of submitochondrial particles of platelets and the hydrolytic activity of F~0~/F~1~-ATPase.

Blood samples
-------------

Peripheral blood (10 mL) samples were obtained from all study participants after an 8-h overnight fast. Serum and platelets were separated and stored at --80°C until processing.

Products of LPO and NO
----------------------

Levels of LPO were evaluated using a commercially available kit (FR12; Oxford Biomedical Research, Oxford, MI, USA) according to the manufacturer\'s instructions. This assay is based on the reaction of the chromogenic reagent *N*-methyl-2-phenylindole with malondialdehyde (MDA) and 4-hydroxyalkenals (4HDA). Briefly, 200 μL serum was added to 455 μL of *N*-methyl-2-phenylindol in acetonitrile (Reagent 1) diluted with ferric acid in methanol. Samples were agitated before 105 μL methanesulfonic acid was added, with the mixture incubated at 45°C for 60 min. Samples were then centrifuged at 15 000*g* for 10 min at room temperature. Then, 200 μL supernatant was placed in a microplate and the absorbance of the sample was measured at 586 nm using a Synergy HT Multi-detection microplate reader (BioTek Instruments, Winooski, VT, USA). Standard curves using known concentrations of the standard 1,1,3,3-tetra-methoxypropane in Tris-HCl were constructed.

To determine levels of NO catabolites, serum samples were deproteinized by the addition of 6 mg zinc sulfate to a 400-μL aliquot of each sample, agitation for 1 min and centrifugation at 10 000 *g* for 10 min at 4°C. The supernatant was removed and stored at --80°C.[@b11] Levels of NO catabolites were determined using a colorimetric method (Nitric Oxide Assay Kit, user protocol 482650; Calbiochem, a brand of EMD Chemicals Inc., an affiliate of Merck, Darmstadt, Germany), according to the manufacturer\'s instructions. Briefly, 85 μL standard or sample was plated onto a microplate and then 10 μL nitrate reductase and 10 μL of 2 mmol/L NADH were added. Plates were agitated for 20 min at room temperature, after which 50 μL Colorant 1 was added and the samples agitated again, followed by the addition of 50 μL Colorant 2 and agitation at room temperature. The absorbance of the samples was determined at 540 nm using a Synergy HT Multi-detection microplate reader (BioTek Instruments).

Total antioxidant capacity
--------------------------

To determine TAC, a commercially available colorimetric kit was used (Total Antioxidant Power Kit, No. TA02.090130, Oxford Biomedical Research) according to the manufacturer\'s instructions. Standards and samples were diluted 1:40 using dilution buffer provided in the kit, and 200 μL was placed in each well of a microplate. A reference value was obtained by determining the absorbance of the plates at 450 nm, after which 50 μL copper solution was added and samples were incubated for 3 min at room temperature. Then, 50 μL stop solution was added and absorbance determined again at 450 nm. Results for TAC are expressed as mmol/L uric acid equivalents. The dilution factor was considered in the final results.

Catalase
--------

To determine catalase activity, 500 μL substrate (10 mmol/L of H~2~O~2~) was added to 30 μL diluted standard or sample. Erythrocytes were incubated for 1 min at room temperature before the addition of 500 μL stop reagent (Bioxytech Catalase-520, catalogue no. 21042; OXIS International, Foster City, CA, USA). Assay tubes were and mixed by inversion and then 20 μL of each reaction mixture was placed in another assay tube. Finally, 2 mL horseradish peroxidase-reactive chromogen was added to the samples, which were mixed by inversion, and incubated for 10 min at room temperature. The absorbance of the samples was determined at 520 nm using a Synergy HT Multi-detection microplate reader (BioTek Instruments).

Glutathione peroxidase
----------------------

Glutathione peroxidase activity was determined using a commerically available kit (Bioxytech GPx-340, catalogue no. 21017; OXIS International). Determination of GPx activity was based on the oxidation of reduced glutathione in presence of *tert*-butyl hydroperoxide, glutathione reductase, and NADPH. The decrease in absorbance at 340 nm following substrate addition was recorded, with the rate of decrease in absorbance directly proportional to GPx activity in the samples.

Fluidity of the submitochondrial membrane in platelets
------------------------------------------------------

Submitochondrial membranes of platelets were obtained by centrifuging blood samples at 2980*g* for 15 min at 4°C. The supernatant was removed and 200 μL cold buffer was added (composition \[in mmol/L\]: NaCl 140; KCl 4.7; MgCl~2~ 1.2; KH~2~PO~4~ 1.2; dextrose 11; HEPES 15) to the pellet and the samples homogenized. An aliquot of 70-µL of the samples, containing platelets, was stored at --80°C. Membrane fluidity was evaluated by incorporation of 1,3 dipyrenylpropane (DPyP) into the biological membranes.[@b12] Briefly, 2 mL Tris-HCl buffer (pH 7.8; 10 mmol/L) was added to a 35-μL aliquot of the submitochondrial membranes and mixed with a pipette at 24°C. Using a fluorescence spectrophotometer (L550B; Perkin-Elmer, Waltham, MA, USA), the fluorescence intensity of the monomer (I~m~) and excimer (I~e~) were determined at 395 and 494 nm, respectively. Then, 5 μL (0.1 μg) DPyP was added to the samples, which were incubated at room temperature in the dark for 3 h to enable incorporation of DPyP into the membranes. Fluorescence intensity second was again determined at 395 and 494 nm, and the I~e~/I~m~ ratio calculated. The ratio I~e~/I~m~ is directly related to membrane fluidity.

Hydrolysis of ATP
-----------------

The hydrolytic activity of mitochondrial F~0~/F~1~-ATPase was measured as the liberation of inorganic phosphate from platelet mitochondria. Briefly, 3 mmol/L MgCl~2~, 30 μL sample and 20 μL ATP (100 mmol/L) were added to 1 mL ATPase buffer (125 mmol/L KCl, 40 mmol/L of 3-\[*N*-morpholino\]propanesulfonic acid \[MOPS\], pH 8) and agitated. The tubes were incubated at 40°C for 10 min to permit the reaction to occur. The activity of the ATPase was stopped by the addition of 200 μL of 30% trichloroacetic acid. Samples were centrifuged at 1160*g* for 10 min at room temperature. Then, 800 μL supernatant was mixed with 1 mL of 3.3% ammonium molybdate and 100 μL of 10% ferrous sulfate. Samples were incubated for 20 min at room temperature before absorbance was determined at 660 nm. Results are expressed as nmol phosphate.

Statistical analysis
--------------------

Results are expressed as the mean ± SEM (standard error of the mean). The significance of differences between groups was evaluated using Student\'s *t*-test or the Mann--Whitney test, as appropriate. Multivariate analysis (ANOVA) or the Kruskal-Wallis test were used to compare values among patient groups with mild, moderate and severe NPDR. Frequencies were determined per category, as well as percentages and the χ^2^ (or Fisher\'s exact) test. Spearman\'s correlation test was performed to establish the non-parametric measure of statistical dependence between variables. *P* \< 0.05 was considered significant; the confidence interval was 95%.

Ethical considerations
----------------------

This study was performed in accordance with the updated Declaration of Helsinki (<http://www.wma.net/es/30publications/10policies/b3/17c.pdf>, accessed January 2011) and in agreement with local and national laws (Mexico). Coded numbers were assigned to ensure patient confidentiality. The study protocol and informed consent were reviewed and approved by the Ethics and Research Committee of the Social Security Institute of Mexico (registration no. R-2012-785-040).

Results
=======

As indicated in Table [1](#tbl1){ref-type="table"}, patients with mild NPDR were significantly older than the other patient groups and control. However, there were no significant differences among patients with mild, moderate, and severe NPDR in terms of demographics, metabolic and hemodynamic parameters, intraocular pressures, liver enzymes, renal function, and lipid profiles (Table [1](#tbl1){ref-type="table"}). Uric acid levels increased with the severity of the retinopathy (*P* \< 0.05). Glucose and HbA1c levels were high in all three groups with NPDR compared with levels in healthy volunteers, which could indicate incomplete assistance by health services or inadequate self-management. All patients were obese and had dyslipidemia, with decreased high-density lipoprotein--cholesterol and increased low-density lipoprotein, total cholesterol and triglyceride levels.

###### 

Demographic data and results of laboratory tests

                             Non-proliferative diabetic retinopathy   *P*-value                              
  -------------------------- ---------------------------------------- ------------------ ------------------- ----
  No. (%) men/women          7 (58%)/5 (42%)                          12 (67%)/6 (33%)   19 (48%)/11 (52%)   NS
  Age (years)                61.58 ± 1.81                             58.72 ± 1.92       58.61 ± 2.09        NS
  Duration of DM (years)     14.17 ± 1.66                             14.22 ± 1.46       15.00 ± 1.27        NS
  BMI (kg/m^2^)              27.32 ± 1.00                             29.32 ± 0.66       28.00 ± 1.00        NS
  SBP (mmHg)                 122.83 ± 4.86                            130.05 ± 3.57      140.00 ± 4.05       NS
  DBP (mmHg)                 77.58 ± 2.80                             78.72 ± 2.12       81.00 ± 1.92        NS
  RIOP (mmhg)                15.75 ± 0.78                             15.33 ± 0.47       15.00 ± 0.45        NS
  LIOP (mmHg)                15.80 ± 0.72                             15.80 ± 0.48       15.00 ± 0.45        NS
  HbA1c (%)                  8.21 ± 0.50                              8.98 ± 0.40        9.00 ± 0.46         NS
  Glucose (mg/dL)            123.66 ± 6.29                            148.77 ± 11.76     142.00 ± 13.54      NS
  Urea (mg/dL)               27.75 ± 2.24                             38.44 ± 3.50       37.00 ± 2.58        NS
  Creatinine (mg/dL)         0.81 ± 0.05                              0.89 ± 0.06        1.00 ± 0.06         NS
  Uric acid (mg/dL)          5.06 ± 0.32                              5.78 ± 0.20        6.00 ± 0.27         NS
  AST (IU/L)                 28.08 ± 3.04                             28.11 ± 1.96       31.00 ± 2.49        NS
  ALT (IU/L)                 31.00 ± 3.09                             32.00 ± 3.43       31.00 ± 2.34        NS
  Total bilirubin (mg/dL)    0.56 ± 0.06                              0.54 ± 0.04        0.46 ± 0.03         NS
  Direct bilirubin (mg/dL)   0.24 ± 0.03                              0.26 ± 0.03        0.18 ± 0.03         NS
  TC (mg/dL)                 167.41 ± 8.93                            199.66 ± 9.69      202.81 ± 7.87       NS
  LDL (mg/dL)                90.55 ± 8.93                             103.70 ± 6.86      123.75 ± 16.93      NS
  HDL (mg/dL)                43.08 ± 2.62                             42.38 ± 1.61       46.10 ± 3.56        NS
  TG (mg/dL)                 168.91 ± 25.22                           271.22 ± 32.46     244.15 ± 30.81      NS

Unless indicated otherwise, data are the mean ± SEM (standard error of the mean).

DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; RIOP, right intraocular pressure; LIOP, left intraocular pressure; AST, aspartate amino transferase; ALT, alanine amino transferase; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides.

Lipid peroxidation products
---------------------------

Levels of LPO products in healthy controls were 0.98 ± 0.13 μmol/L. These increased significantly with the severity of retinopathy from 1.42 ± 0.08 to 2.49 ± 0.05, and 3.29 ± 0.05 μmol/L (mild, moderate, and severe NPDR, respectively; *P* \< 0.017; Fig. [1](#fig01){ref-type="fig"}a), suggesting the presence of oxidative stress in NPDR. Because LPO is a well-established mechanism of cellular lesions, these findings suggest cellular and systemic oxidative stress.

![Oxidants (a,b) and antioxidants (c--e) in type 2 diabetes mellitus patients with mild, moderate, or severe non-proliferative diabetic retinopathy (NPDR). (a) Products of lipid peroxidation (LPO), given as malondialdehyde (MDA) and 4-hydroxyalkenals (4HDA), were highest in patients with severe NPDR (3.29 ± 0.05 μmol/L; *P* \< 0.017 compared with control), as were levels of (b) nitric oxide (NO) catabolites (45.62 ± 1.27 pmol/mL; *P* \< 0.0001 compared with control). (c) Total antioxidant capacity (TAC) was significantly decreased in all three groups of NPDR, with the greatest decrease seen in patients with severe NPDR (7.98 ± 0.48 mEq/mL; *P* \< 0.0001 compared with control). (d,e) Erythrocyte catalase and glutathione peroxidase (GPx) activity was higher in patients with NPDR, with maximum catalase activity seen in patients with mild retinopathy (142 ± 6 U/mg protein; *P* \< 0.0001 compared with control), whereas GPx activity was highest in those with severe retinopathy (117 ± 15 U/min/mg protein; *P* \< 0.0001 compared with control). Data are the mean ± SE. \**P* \< 0.05 compared with healthy volunteers.](jdb0006-0167-f1){#fig01}

Nitrites/nitrates
-----------------

Levels of the NO catabolites nitrites/nitrates (NO~x~) in healthy controls were 12.31 ± 1.15 pmol/mL. The NO~x~ levels increased significantly with the severity of retinopathy from 25.32 ± 0.46 to 36.56 ± 0.05, and 45.62 ± 1.27 pmol/mL (mild, moderate, and severe NPDR, respectively; *P* \< 0.0001; Fig. [1](#fig01){ref-type="fig"}b). These findings suggest nitrosative stress in NPDR.

Total antioxidant capacity
--------------------------

The TAC offers a complete picture of the function of cellular antioxidant systems. In healthy controls, uric acid values were 22.41 ± 1.10 mEq/mL, which decreased significantly with the severity of retinopathy from 16.05 ± 0.17 to 12.90 ± 0.55, and 7.98 ± 0.48 mEq/mL (mild, moderate, and severe NPDR, respectively; *P* \< 0.0001; Fig. [1](#fig01){ref-type="fig"}c).

Catalase activity
-----------------

Erythrocyte catalase activity increased significantly in all three NPDR groups (142.12 ± 6.30, 136.45 ± 4.83, and 139.40 ± 4.42 U/mg protein for mild, moderate, and severe NPDR, respectively) compared with the healthy controls (94.17 ± 1.58 U/mg protein; *P* \< 0.0001; Fig. [1](#fig01){ref-type="fig"}d).

Glutathione peroxidase activity
-------------------------------

In the healthy controls, GPx activity was 35.13 ± 2.74 U/min/mg protein. As for catalase activity, GPx activity increased significantly in T2DM patients with mild, moderate, and severe NPDR (100.32 ± 20.68, 95.32 ± 16.54, and 117.13 ± 14.84 U/min/mg protein, respectively; *P* \< 0.0001 vs control; Fig. [1](#fig01){ref-type="fig"}e). It is possible that the greater catalase and GPx activity in NPDR could be due to a compensatory response to the oxidative stress caused by a persistent metabolic disorder as a result of uncontrolled pharmacological treatment of T2DM.

Submitochondrial membrane fluidity
----------------------------------

The I~e~/I~m~ ratio in the healthy control group was 0.24 ± 0.01. The I~e~/I~m~ ratio decreased significantly in T2DM patients with mild, moderate, and severe NPDR (0.12 ± 0.01, 0.16 ± 0.02, and 0.13 ± 0.01, respectively; *P* \< 0.0001). The decrease in fluidity compared with the control group could be related to the effect that the fluidity of the membrane has on membrane potential induced by the increase in HbA1c, dyslipidemia, oxidative stress or their combination (Fig. [2](#fig02){ref-type="fig"}a).

![Mitochondrial function in type 2 diabetes mellitus patients with mild, moderate, or severe non-proliferative diabetic retinopathy (NPDR). (a) The fluorescence ratio of the excimer (I~e~) to monomer (I~m~) decreased significantly in patients with NPDR, with the greatest decrease seen in patients with mild retinopathy (I~e~/I~m~ 0.12 ± 0.01; *P* \< 0.0001 compared with control). (b) Significant increases were seen in the hydrolytic activity of F~0~/F~1~-ATPase in all three groups of NPDR, with the greatest increase seen in patients with mild retinopathy (300 ± 38 nmol PO~4~; *P* \< 0.0001 compared with control). This could mean lower ATP synthesis with excessive production of cellular catabolism. Data are the mean ± SE. \**P* \< 0.05 compared with healthy volunteers.](jdb0006-0167-f2){#fig02}

Hydrolysis of F~0~/F~1~-ATPase
------------------------------

Significant increases were observed in the hydrolytic activity of F~0~/F~1~-ATPase in T2DM patients with mild, moderate, and severe NPDR (301 ± 38, 250 ± 29, and 265 ± 30 nmol PO~4~, respectively) compared with the control group (185 ± 8 nmol PO~4~; *P* \< 0.001; Fig. [2](#fig02){ref-type="fig"}b). These results suggest a mitochondrial catabolic state, associated with oxidative stress.

Spearman\'s correlation test
----------------------------

We found a positive correlation between elevated levels of LPO and NO, demonstrating the presence of oxidative and/or nitrosative stress that could contribute to the pathogenesis and progression of DR (Fig. [3](#fig03){ref-type="fig"}a). In addition, there was a positive correlation between uric acid and LPO levels, which may reflect a compensatory mechanism for the oxidative state caused by the persistent hyperglycemia (Fig. [3](#fig03){ref-type="fig"}c). Furthermore, there were positive correlations between LPO and NO~x~ with a decrease in TAC (Fig. [3](#fig03){ref-type="fig"}b,e). There was an increased consumption of TAC defenses with progressive increases in LPO and NO due to lack of metabolic control. There was also a positive correlation between increased GPx and catalase activity. This could be related to a compensatory mechanism to prevent tissue damage via an increase in these two antioxidant enzyme systems (Fig. [3](#fig03){ref-type="fig"}d).

![Results of Spearman\'s correlation tests. Significant positive correlations were found between (a) the products of lipid peroxidation (LPO) and nitric oxide (NO), as well as between (b) LPO and diminished total antioxidant capacity (TAC; *P* \< 0.010). In addition, significant positive correlations were found between (c) LPO and uric acid (*P* \< 0.025), (d) increased catalase and glutathione peroxidase (GPx) activity (*P* \< 0.007), and (e) increased NO~x~ levels and TAC (*P* \< 0.010). We can assume that there is oxidant, antioxidant, and mitochondrial dysregulation in chronic type 2 diabetes mellitus.](jdb0006-0167-f3){#fig03}

Discussion
==========

The time to evolution of DM in the present study was \>14 years, which could have favored the oxidative deregulation found. The chronicity of DM is an important risk factor for the development of DR.[@b13] All patients had hyperglycemia despite close medical attention; this lack of metabolic control allows us to consider the biological posibility of finding diverse alterations related to hyperglycemia and the duration of DM. Chronic hyperglycemia alters the homeostasis of vascular endothelial cells and causes changes in the expression of genes that incite DR,[@b14] favoring early functional changes that augment the permeability of the basal membrane of the retina, with endothelial cell dysfunction and increased oxidative stress.[@b15]

Increases in MDA + 4HDA in poorly controlled and long-term T2DM can cause DR.[@b16] In the present study, we found LPO levels increased progressively with the severity of retinopathy. Periodic evaluation of LPO in DM could contribute to the early identification of oxidative stress and possibly diminish cell death as a result of the application of therapeutic interventions that tend to modify and control the metabolic state and oxidative stress. The NO~x~ levels showed the same pattern as LPO, with progressive increases seen with the increasing severity of retinopathy. Apparently, the biochemical changes induced by hyperglycemia resulted in augmentation of the oxidative and/or nitrosative stress,[@b17] which is supported by evidence that increased levels of markers of oxidative stress are key factors in the development of DR, directly affecting the retinal microvasculature in hyperglycemia.[@b18],[@b19]

In contrast, we found progressive decreases in TAC with the severity of NPDR. It has been proposed that oxidative stress and diminished antioxidant defenses are associated with the progression of DR and PDR.[@b20] If concomitant oxidant deficiency is produced, oxidative stress can result in tissue damage; thus, it may be of use to conduct clinical trials to evaluate the benefit of the administration of complementary antioxidants to patients in controlling oxidative stress and the progression of DR.

Uric acid is the final product of oxidation in the metabolism of purines. In the present study there was a progressive increase in uric acid levels with the severity of retinopathy, and a positive correlation between uric acid levels and increases in LPO. Increases in uric acid could have a compensatory role in the oxidative state caused by hyperglycemia,[@b21] because the uric acid has antioxidant activity by participating in the detoxification of lipid hydroperoxides into non-toxic alcohols.[@b22],[@b23]

Erythrocyte catalase activity was significantly and inversely increased in relation to the TAC, depending on the severity of the retinopathy (*P* \< 0.0001). It has been reported that SOD and catalase activity in leukocytes from T2DM patients with DR were inferior compared with leukocytes from healthy subjects and diabetic patients without DR.[@b24] In contrast with the decrease in GPx and SOD activity found in diabetic patients with microvascular complications,[@b25] our results demonstrate progressive increases in erythrocyte GPx activity with the severity of NPDR, possibly indicating a compensatory role in the oxidative and/or nitrosative state. However, we consider that the deregulation among the oxidants and/or antioxidants caused by persistent hyperglycemia could contribute to the appearance of microvascular complications present in T2DM. A possible explanation for the significant increase in the two antioxidant systems (GPx and catalase) and the significant decrease in TAC in the present study could be related to compensatory mechanisms for the oxidative state, as reported previously.[@b26]

The fluidity of the submitochondrial particles of platelets was significantly diminished in patients with mild, moderate, and severe NPDR, suggesting that the membranes are very sensitive to oxidative and/or nitrosative stress, as has been previously reported in Alzheimer\'s disease.[@b12] In animal models, it has been reported that under hyperglycemic conditions the mitochondria of the retinal pericytes show significant fragmentation and metabolic dysfunction; these changes could play an important role in accelerating the death, by apoptosis, of the retinal pericytes in T2DM.[@b27],[@b28] Possible pathogenic mechanisms involved in the platelet dysfunction include increased viscosity of the blood associated with changes in cellular deformity and the pathological interaction between leukocytes and endothelia. Chronic hyperglycemia affects cellular function and the extracellular matrix by: (i) increasing the activity of the polyol pathway; (ii) changing the intracellular redox state; (iii) activating protein kinase C; (iv) non-enzymatic glycation; and (v) increasing free radicals.[@b29]

The hydrolytic activity of F~0~/F~1~-ATPase is normally quite low. In the present study, F~0~/F~1~-ATPase activity in healthy individuals was 185 ± 8 nmol PO~4~, and this increased significantly in all three NPDR groups, with the greatest activity seen in patients with mild NPDR. This suggests an important deregulation between the production and consumption of cellular energy (catabolism), possibly caused by the persistent hyperglycemic state and chronicity of DM. In Alzheimer\'s disease, it has been suggested that functional changes in mitochondrial F~0~/F~1~-ATPase are caused by: (i) the physical separation of F~0~ and F~1~ segments; (ii) changes in the assembly of the regulatory subunits of the enzyme; and (iii) an increase in the fluidity of the internal mitochondrial membrane.[@b30] In addition, we believe that excess in LPO and NO~x~ could also contribute to the increased F~0~/F~1~-ATPase hydrolytic activity.

One must consider that the adequate control of T2DM should include maintenance of normal glucose levels, thus preventing or delaying the appearance of microvascular complications of the retina. We believe that understanding the distinct molecular mechanisms responsible for mitochondrial damage could help identify management alternatives to postpone or prevent the DR that threatens the vision of people who suffer from DM.
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